A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer

2024-515608-38-00 Protocol PH-ACP3GA-01/24 Human pharmacology (Phase I) - First administration to humans Ended

Start 19 Mar 2025 · End 3 Oct 2025 · Status Ended · 1 EU/EEA countries · 3 sites · Protocol PH-ACP3GA-01/24

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 20
Countries 1
Sites 3

Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

Key facts

Sponsor
Philogen S.p.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
19 Mar 2025 → 3 Oct 2025
Decision date (initial)
2024-11-27
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Philogen S.p.A.

Sponsor organisation
Philogen S.p.A.
Address
Piazza La Lizza 7
City
Siena
Postcode
53100
Country
Italy

Scientific contact point

Organisation
Philogen S.p.A.
Contact name
Jacqueline Mock

Public contact point

Organisation
Philogen S.p.A.
Contact name
Jacqueline Mock

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 20 3
Rest of world 0

Investigational sites

Italy

3 sites · Ended
Fondazione IRCCS Istituto Nazionale Dei Tumori
Diagnostic Imaging and Radiotherapy/Nuclear Medicine, Via Giacomo Venezian 1, 20133, Milan
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Department of Medicine and Surgery and Nuclear Medicine, Piazza Oms 1, 24127, Bergamo
Ospedale San Raffaele S.r.l.
Medicina Nucleare, Via Olgettina 60, 20132, Milan

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2025-03-19 2025-10-03 2025-04-08 2025-09-30

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-09 Italy Acceptable
2024-11-25
2024-11-27
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-11-18 Italy Acceptable
2024-11-25
2025-11-18